<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004887</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067562</org_study_id>
    <secondary_id>CHNT-PC/MIC</secondary_id>
    <secondary_id>EU-99046</secondary_id>
    <nct_id>NCT00004887</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery</brief_title>
  <official_title>A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not yet known whether paclitaxel and carboplatin is more&#xD;
      effective than standard chemotherapy for advanced non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and&#xD;
      carboplatin chemotherapy with that of standard chemotherapy in treating patients who have&#xD;
      stage III or stage IV non-small cell lung cancer that cannot be removed during surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the one and two year survival of patients with inoperable advanced non-small&#xD;
           cell lung cancer treated with paclitaxel and cisplatin versus standard platinum therapy.&#xD;
&#xD;
        -  Compare the toxic effects of these two regimens in this patient population.&#xD;
&#xD;
        -  Compare the performance status, tumor response, and quality of life in these patients&#xD;
           after these treatment regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, stage of disease (IIIA vs IIIB vs IV), or performance status (ECOG O vs 1 vs 2 vs 3).&#xD;
&#xD;
      Patients are randomized to one of two treatment arms:&#xD;
&#xD;
        -  Arm I: Patients receive paclitaxel IV over 3 hours, followed by carboplatin IV over 30&#xD;
           minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive mitomycin IV, ifosfamide IV over 3 hours, and cisplatin IV over&#xD;
           1 hour on day 1 OR mitomycin IV, vinblastine IV, and cisplatin IV over 4 hours on day 1.&#xD;
&#xD;
      Treatment continues every 3 weeks for up to 4 courses in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed before each treatment course.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 300 patients (150 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1999</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed inoperable advanced non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIA, IIIB, or IV&#xD;
&#xD;
               -  Not eligible for curative radiotherapy or surgery&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  No bony lesions as only site of measurable disease&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 (ECOG 3 allowed in some cases)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT no greater than 3 times ULN (no greater than 5 times ULN for liver&#xD;
             metastases)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious systemic disorder that would preclude compliance&#xD;
&#xD;
          -  No second malignancy except carcinoma in situ of the cervix or adequately treated&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  No peripheral neuropathy, significant neurological disorders (e.g., seizures), or&#xD;
             psychiatric disorders&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed if measurable disease outside of irradiated field&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Thatcher, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2000</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>July 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

